Beijing Sun Novo Pharmaceutical Research Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 2.04%

Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) has an Asset Resilience Ratio of 2.04% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Beijing Sun Novo Pharmaceutical Research's working capital to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥47.00 Million
≈ $6.88 Million USD Cash + Short-term Investments

Total Assets

CN¥2.30 Billion
≈ $336.59 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how Beijing Sun Novo Pharmaceutical Research Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Beijing Sun Novo Pharmaceutical Research's balance sheet.

Liquid Assets Composition Over Time

This chart breaks down Beijing Sun Novo Pharmaceutical Research Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Beijing Sun Novo Pharmaceutical Research total liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥47.00 Million 2.04%
Total Liquid Assets CN¥47.00 Million 2.04%

Asset Resilience Insights

  • Limited Liquidity: Beijing Sun Novo Pharmaceutical Research Co Ltd maintains only 2.04% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Beijing Sun Novo Pharmaceutical Research Co Ltd Industry Peers by Asset Resilience Ratio

Compare Beijing Sun Novo Pharmaceutical Research Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM
Drug Manufacturers - Specialty & Generic 2.79%
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
Beijing Tongrentang Co Ltd
SHG:600085
Drug Manufacturers - Specialty & Generic 2.51%
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
Drug Manufacturers - Specialty & Generic 3.47%
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
Drug Manufacturers - Specialty & Generic 20.44%
Harbin Pharmaceutical Group Co Ltd
SHG:600664
Drug Manufacturers - Specialty & Generic 0.97%
Kangmei Pharmaceutical Co Ltd
SHG:600518
Drug Manufacturers - Specialty & Generic 0.00%

Annual Asset Resilience Ratio for Beijing Sun Novo Pharmaceutical Research Co Ltd (2021–2025)

The table below shows the annual Asset Resilience Ratio data for Beijing Sun Novo Pharmaceutical Research Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 3.28% CN¥75.00 Million
≈ $10.97 Million
CN¥2.28 Billion
≈ $334.34 Million
+1.77pp
2024-12-31 1.51% CN¥30.00 Million
≈ $4.39 Million
CN¥1.99 Billion
≈ $290.81 Million
-0.10pp
2023-12-31 1.61% CN¥30.00 Million
≈ $4.39 Million
CN¥1.86 Billion
≈ $272.62 Million
+0.71pp
2022-12-31 0.90% CN¥13.11 Million
≈ $1.92 Million
CN¥1.46 Billion
≈ $214.10 Million
-11.79pp
2021-12-31 12.68% CN¥157.60 Million
≈ $23.06 Million
CN¥1.24 Billion
≈ $181.84 Million
--
pp = percentage points

About Beijing Sun Novo Pharmaceutical Research Co Ltd

SHG:688621 China Drug Manufacturers - Specialty & Generic
Market Cap
$1.22 Billion
CN¥8.35 Billion CNY
Market Cap Rank
#8117 Global
#1885 in China
Share Price
CN¥74.55
Change (1 day)
-0.59%
52-Week Range
CN¥47.96 - CN¥78.30
All Time High
CN¥128.22
About

Beijing Sun-Novo Pharmaceutical Research Co., Ltd., a contract research company, engages in the research and development of drugs in China. The company operates an external preparation platform that focuses on the research and development of new drugs and generic drugs for skin external preparations; children's clinical data bridging research center; pediatric drug research and development platfo… Read more